CBLI:NSD-Cleveland BioLabs, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.03

Change

+0.29 (+7.75)%

Market Cap

USD 0.05B

Volume

0.93M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+4.79 (+2.07%)

USD60.31B 22.73 18.26
REGN Regeneron Pharmaceuticals, Inc

+8.38 (+1.57%)

USD56.97B 19.57 14.64
MRNA Moderna, Inc

+0.13 (+0.10%)

USD49.47B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-0.97 (-0.61%)

USD34.71B 36.83 33.83
SGEN Seagen Inc

+2.02 (+1.07%)

USD33.79B 71.29 70.76
RPRX Royalty Pharma plc

-1.50 (-2.89%)

USD32.42B 22.60 11.90
BGNE BeiGene, Ltd

+6.12 (+1.72%)

USD32.06B N/A N/A
GMAB Genmab A/S

-1.07 (-2.41%)

USD28.72B 26.59 3.08
BNTX BioNTech SE

-1.47 (-1.40%)

USD25.21B -99,999.99 N/A
INCY Incyte Corporation

+2.41 (+2.56%)

USD20.58B 47.64 35.20

ETFs Containing CBLI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.81% 59% F 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.81% 59% F 76% C
Trailing 12 Months  
Capital Gain 303.00% 94% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 303.00% 94% A 95% A
Trailing 5 Years  
Capital Gain 5.77% 50% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.77% 50% F 26% F
Average Annual (5 Year Horizon)  
Capital Gain 31.06% 68% D+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.06% 68% D+ 83% B
Risk Return Profile  
Volatility (Standard Deviation) 109.72% 20% F 9% F
Risk Adjusted Return 28.31% 60% D- 53% F
Market Capitalization 0.05B 10% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 177.00 7% F 8% F
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -18.28 73% C 83% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -110.49% 26% F 10% F
Return on Invested Capital 85.42% 98% A+ 98% A+
Return on Assets -47.85% 18% F 6% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.57 81% B- 79% C+
Short Percent 3.47% 72% C- 49% F
Beta 0.64 85% B 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector